Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Seasonal/perennial allergic rhinitis (SAR/PAR) is a common childhood illness. One of the leading therapies for the treatment of SAR/PAR is intranasally inhaled corticosteroids (ICS). One of the major long-term safety concerns is whether ICS interferes with normal growth in allergic rhinitis children. Recent evidence suggests that nasal ICS may cause decreased growth. However, the effect of nasal ICS on long-term growth and the attainment of final adult height is unknown. Another potential systemic adverse effect of ICS use is suppression of the hypothalamic-pituitary-adrenal axis function. The primary hypothesis of this study is that triamcinolone acetonide aqueous nasal spray (TAA) will have no effect on measured adult height in relation to target adult height in children with allergic rhinitis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
6 Years to 13 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male/Female aged 6-13 years of age
Diagnosis of SAR/PAR, with symptoms within the past 3 months
Positive skin test to inhalant allergen with negative saline control
No previous use of intranasal inhaled, oral, IV or topical steroid use within past 6 months.
If the subject has asthma, only mild intermittent (per NAPP) guidelines treated with PRN bronchodilator
screening height outside the 5th and 95th percentiles
History of abnormal growth
Any other chronic condition beside allergic rhinitis or mild intermittent asthma
Subject who has insufficient allergic rhinitis symptoms to require daily therapy during the trial.
Subject with a known hypersensitivity to any active ingredients or excipents in the study medications
Subject with nasal candidiasis, acute or chronic sinusitis, significant nasal polyposis (impairs nasal breathing), or other gross anatomical deformity of the nose sufficient to impair nasal breathing (e.g., deviated septum)
Subjects with a history of substance abuse, mental illness or retardation
Subjects with a history or presence of glaucoma or posterior subcapsular cataract
Subjects with nocturnal enuresis.
Use of Theophylline, Intal/Tilade or leukotriene modifiers.